---
watermark: ORIRO
disable-model-invocation: true
name: industry-pharma
provider: ORIRO.ai
copyright: Copyright (c) 2026 ORIRO.ai
description: >









  Pharmaceutical industry — drug development, clinical trials, regulatory pathway, IP, and pharma business model.
  Sources: Industry-specific trade associations, regulatory guidance, and publicly available resources.
---

# Pharmaceutical Industry

## Drug development process

### Discovery and preclinical (5-10 years)

Target identification: Which biological target (protein, receptor) to address?
Hit/lead identification: Screen millions of compounds for activity at target.
Lead optimization: Improve potency, selectivity, safety, and bioavailability.
Preclinical testing: Animal studies for safety and preliminary efficacy.
IND (Investigational New Drug) application filed with FDA.

### Clinical trials (6-12 years)

**Phase I:** First in humans. ~20-100 healthy volunteers. Safety, dosing, pharmacokinetics. Success rate: ~70%.
**Phase II:** Small patient population (~100-500). Preliminary efficacy, optimal dose, safety. Success rate: ~40%.
**Phase III:** Large randomized controlled trial (~1,000-3,000+ patients). Efficacy vs. standard of care. Success rate: ~65%.
**Overall Phase I-III success:** Only ~12% of drugs that enter clinical trials make it to approval.

### FDA review

**NDA/BLA submission:** New Drug Application (small molecules) or Biologics License Application (biologics).
PDUFA date: Review deadline (typically 12 months, 6 months for priority review).
Advisory committee: External experts advise FDA (non-binding).
**Priority review, Breakthrough therapy, Accelerated approval, Fast track:** Expedited pathways for serious conditions with unmet needs.

## Key regulatory concepts

**Bioequivalence:** Generic drugs must demonstrate equivalent absorption to brand drug. 80-125% CI on pharmacokinetic parameters.
**505(b)(2) pathway:** Uses published data/prior approvals for reformulations or new indications.
**Orphan drug designation:** For diseases affecting < 200,000 US patients. Benefits: 7-year exclusivity, fee waivers, tax credits.
**Post-market surveillance:** Phase IV studies and safety monitoring after approval.

## Intellectual property

**Patent term:** 20 years from filing date. Effective patent life reduced by development time.
**Data exclusivity:** Separate from patents. FDA won't approve generics for 5 years (NCE), 3 years (new indication), 12 years (biologics).
**Patent cliff:** When key patents expire, generic/biosimilar competition can drop prices 80-90%.
**Evergreening:** Extending patent protection through formulation changes, new indications, pediatric exclusivity.

## Business model

**High-risk, high-reward:** Average R&D cost per approved drug: $1-3 billion. Only 1 in 10,000 screened compounds reaches market.
**Pricing power:** For novel drugs with no competition and significant clinical benefit, manufacturers have significant pricing power in US market (not in most other countries).
**US vs. international pricing:** US prices often 3-10× higher than other developed countries due to lack of centralized price negotiation.
**Generic market:** ~90% of US prescriptions by volume are generics. ~20% by spending.
**Biosimilars:** Generic equivalents to biologics. More complex, more expensive to develop than small molecule generics.

Sources: FDA (fda.gov — free drug approvals, guidance documents), Drugs@FDA database (free), PhRMA (phrma.org — free industry data), EvaluatePharma (limited free data), STAT News (free healthcare journalism)